Inventor · disambiguated record
Christopher Mayne
Also filed as: MAYNE CHRISTOPHER · MAYNE CHRISTOPHER GLENN
12 granted patents·11 pending applications·42 citations·filing 2019–2024
88Inventor score
Top patents by PatentIndex Score
23 records- 0196US11634407B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Apr 25, 2023·5 cites·66 claims
- 0296US11149007B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted Oct 19, 2021·14 cites·41 claims
- 0394US11325889B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2019·Granted May 10, 2022·11 cites·35 claims
- 0493US11873283B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 16, 2024·2 cites·34 claims
- 0593US11739075B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Aug 29, 2023·3 cites·17 claims
- 0693US11560371B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2021·Granted Jan 24, 2023·3 cites·18 claims
- 0790US11873295B2Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of diseasePETRA PHARMA CORP·Filed 2022·Granted Jan 16, 2024·3 cites·125 claims
- 0881US12404241B2Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Sep 2, 2025·0 cites·16 claims
- 0981US11649227B2Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of diseasePETRA PHARMA CORP·Filed 2021·Granted May 16, 2023·1 cites·20 claims
- 1078US2025188056A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2024·Application pending·0 cites
- 1176US12103920B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Oct 1, 2024·0 cites·15 claims
- 1272US12227490B2Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2023·Granted Feb 18, 2025·0 cites·18 claims
- 1369US2024051948A1Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of diseasePETRA PHARMA CORP·Filed 2023·Application pending·0 cites
- 1468US2024383878A1Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of diseasePETRA PHARMA CORP·Filed 2024·Application pending·0 cites
- 1566US2023286960A1Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of diseasePETRA PHARMA CORP·Filed 2023·Application pending·0 cites
- 1664US2025197413A1Rxfp1 receptor agonistsLILLY CO ELI·Filed 2024·Application pending·0 cites
- 1763US2023014445A1Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of diseasePETRA PHARMA CORP·Filed 2022·Application pending·0 cites
- 1861US2025100995A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 1961US2024182460A1Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of diseasePETRA PHARMA CORP·Filed 2023·Application pending·0 cites
- 2059US2024368118A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 2159US2024374591A1Cereblon binding compounds, compositions thereof, and methods of treatment therewithCELGENE CORP·Filed 2022·Application pending·0 cites
- 2258US2024018115A1Allosteric chromenone inhibitors of phosphoinositide 3-kinase (pi3k) for the treatment of diseasePETRA PHARMA CORP·Filed 2023·Application pending·0 cites
- 2356US11878970B2Allosteric chromenone inhibitors of phosphoinositide 3-kinase (PI3K) for the treatment of diseasePETRA PHARMA CORP·Filed 2022·Granted Jan 23, 2024·0 cites·65 claims
Join the waitlist — get patent alerts
Get an alert when Christopher Mayne files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →